Literature DB >> 21360575

The thrombopoietin/MPL pathway in hematopoiesis and leukemogenesis.

Fu-Sheng Chou1, James C Mulloy.   

Abstract

Hematopoietic stem cells (HSC) comprise a small percentage of total hematopoietic cells. Their ability to self-renewal is key to the continuous replenishment of the hematopoietic system with newly formed functional blood cell types while maintaining their multipotential capacity. Understanding the extrinsic signals that are essential to HSC maintenance will provide insights into the regulation of hematopoiesis at its most primitive stage, and with the knowledge applied, will potentially lead to improved clinical transplantation outcomes. In this review, we will summarize the current understanding of the role of the thrombopoietin/MPL signaling pathway in HSC maintenance during adult and fetal hematopoiesis. We will also speculate on the downstream key players in the pathway based on published data, and summarize the role of this pathway in leukemia.
Copyright © 2011 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21360575     DOI: 10.1002/jcb.23089

Source DB:  PubMed          Journal:  J Cell Biochem        ISSN: 0730-2312            Impact factor:   4.429


  20 in total

1.  Eltrombopag inhibits the proliferation of leukemia cells via reduction of intracellular iron and induction of differentiation.

Authors:  Michael Roth; Britta Will; Guillermo Simkin; Swathi Narayanagari; Laura Barreyro; Boris Bartholdy; Roni Tamari; Constantine S Mitsiades; Amit Verma; Ulrich Steidl
Journal:  Blood       Date:  2012-05-24       Impact factor: 22.113

2.  Identification of a new Mpl-interacting protein, Atp5d.

Authors:  Hongyan Liu; Zhenhu Zhao; Yuxu Zhong; Yajun Shan; Xiaohong Sun; Bingzhi Mao; Yuwen Cong
Journal:  Mol Cell Biochem       Date:  2014-03-11       Impact factor: 3.396

3.  Exome sequencing identifies MPL as a causative gene in familial aplastic anemia.

Authors:  Amanda J Walne; Arran Dokal; Vincent Plagnol; Richard Beswick; Michael Kirwan; Josu de la Fuente; Tom Vulliamy; Inderjeet Dokal
Journal:  Haematologica       Date:  2011-12-16       Impact factor: 9.941

4.  The thrombopoietin receptor, MPL, is critical for development of a JAK2V617F-induced myeloproliferative neoplasm.

Authors:  Veena Sangkhae; S Leah Etheridge; Kenneth Kaushansky; Ian S Hitchcock
Journal:  Blood       Date:  2014-10-22       Impact factor: 22.113

5.  CD34 Antigen and the MPL Receptor Expression Defines a Novel Class of Human Cord Blood-Derived Primitive Hematopoietic Stem Cells.

Authors:  Yoshikazu Matsuoka; Masaya Takahashi; Keisuke Sumide; Hiroshi Kawamura; Ryusuke Nakatsuka; Tatsuya Fujioka; Yoshiaki Sonoda
Journal:  Cell Transplant       Date:  2016-11-30       Impact factor: 4.064

6.  [Thrombopoietin promotes megakaryopoiesis via protecting bone marrow endothelial function in patients undergoing chemotherapy for hematological malignancies].

Authors:  Xiaoyuan Zeng; Yingying Jiao; Zongpeng Li; Yujiao Zhang; Jieyu Ye
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2020-08-30

7.  Kras is Required for Adult Hematopoiesis.

Authors:  Alisa Damnernsawad; Guangyao Kong; Zhi Wen; Yangang Liu; Adhithi Rajagopalan; Xiaona You; Jinyong Wang; Yun Zhou; Erik A Ranheim; Hongbo R Luo; Qiang Chang; Jing Zhang
Journal:  Stem Cells       Date:  2016-03-28       Impact factor: 6.277

8.  DNMT3A Arg882 mutation drives chronic myelomonocytic leukemia through disturbing gene expression/DNA methylation in hematopoietic cells.

Authors:  Jie Xu; Yue-Ying Wang; Yu-Jun Dai; Wu Zhang; Wei-Na Zhang; Shu-Min Xiong; Zhao-Hui Gu; Kan-Kan Wang; Rong Zeng; Zhu Chen; Sai-Juan Chen
Journal:  Proc Natl Acad Sci U S A       Date:  2014-02-04       Impact factor: 11.205

9.  Hematopoietic stem cell development, niches, and signaling pathways.

Authors:  Kamonnaree Chotinantakul; Wilairat Leeanansaksiri
Journal:  Bone Marrow Res       Date:  2012-07-30

Review 10.  Thrombopoietin as biomarker and mediator of cardiovascular damage in critical diseases.

Authors:  Enrico Lupia; Alberto Goffi; Ornella Bosco; Giuseppe Montrucchio
Journal:  Mediators Inflamm       Date:  2012-04-05       Impact factor: 4.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.